Adoptive transfer of TCR-transduced T cells in metastatic colorectal cancer

Wafik El-Deiry shared a post on LinkedIn about a recent paper by Steven A. Rosenberg et al. titled “Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results” published in the Nature Medecine.

Authors: Maria Parkhurst, Stephanie L. Goff, Frank J. Lowery, Rachel K. Beyer, Hyunmi Halas, Paul F. Robbins, Todd D. Prickett, Jared J. Gartner, Sivasish Sindiri, Sri Krishna, Nikolaos Zacharakis, Lien Ngo, Satyajit Ray, Alakesh Bera, Ryan Shepherd, Noam Levin , Sanghyun P. Kim, Amy Copeland, Shirley Nah, Shoshana Levi, Neilesh Parikh, Mei Li M. Kwong, Nicholas D. Klemen, James C. Yang, Steven A. Rosenberg.             .

“Exciting preliminary results in Nature Medicine by Dr. Rosenberg at National Cancer Institute in MSS mCRC.

Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results.

‘T cell populations were polyfunctional in that they secreted IFNγ, GM-CSF, IL-2 and granzyme B specifically in response to mutant peptides compared with wild-type counterparts. TCR-transduced cells were detected in the peripheral blood of five patients, including the three responders, at levels ≥10% of CD3+ cells 1 month post-ACT.’ ”

Source: Wafik El-Deiry/LinkedIn

Wafik El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center of Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals.Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.